AORT logo

ARTIVION INC

AORTNYSE
πŸ† #2372 by market capEarnings Feb 10 Β· PostUS Equity
$18.16β–Ό $0.37 (βˆ’2.00%)
Market closed Β· at close
πŸ””
Track AORT
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 2.0%
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$885M
Small Cap
πŸ“ˆRevenue Growth (YoY)
14.0%
Healthy
πŸ“ŠGross Margin
63.3%
High
πŸ’΅FCF Margin
7.9%
Moderate
βš–οΈP/S Ratio
1.8x
Cheap
Otter Score
72
Strong
No chart data available for AORT.

Trading Snapshot

Day Range
$18.13 – $18.81
52-Week Range
$18.12 – $48.25
Volume (shares)
642,096
Avg Volume (shares)
β€”
Shares Outstanding
48.8M
Next Earnings
2027-02-10

Fundamentals Snapshot

Annual Revenue
$441M
Last Q Revenue
$124M
P/E Ratio
β€”
P/S Ratio
1.8x
EPS (TTM)
$-0.36
Dividend Yield
β€”
Dilution (1yr)
+18.4%
AORT logo

ARTIVION INC

AORT
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$441Mβ–² +13.6% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
61.3%β–Ό βˆ’4.3% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$27Mβ–Ό βˆ’31.2% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$839Kβ–Ό βˆ’92.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
49.6Mβ–² +18.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$227Mβ–² +$82M YoY
StockOtter Β· stockotter.space

About ARTIVION INC

Artivion Inc. is a global company that develops, produces, and supplies medical devices and implantable human tissues. Its product range includes BioGlue, a polymer derived from bovine blood protein combined with a cross-linking agent, utilized in cardiac, vascular, neurological, and pulmonary surgical applications. The company also offers heart preservation services and the PhotoFix bovine pericardial patch, in addition to E-vita Open Plus and E-vita Open Neo devices. For the treatment of aortic vascular conditions, Artivion provides specialized stent graft systems. These include E-xtra design engineering systems for aortic vascular diseases, E-nside as an off-the-shelf solution for thoraco-abdominal disease, E-vita THORACIC 3G for endovascular repair of thoracic aortic aneurysms, E-nya for minimally invasive repair of descending aorta lesions, and the E-tegra system for abdominal aortic aneurysms. Furthermore, its offerings address peripheral and renal artery treatments with the E-ventus BX balloon-expandable stent graft and the E-liac system for aneurysmal iliac arteries and their side branches. The company's diverse portfolio extends to synthetic vascular grafts for use in open aortic and peripheral vascular surgeries, PerClot (an absorbable powdered hemostat for surgical procedures), and cardiac laser therapy products for angina management. Preservation services include CryoVein for femoral veins and CryoArtery for femoral arteries. Artivion also manufactures On-X prosthetic aortic and mitral heart valves, along with the On-X ascending aortic prosthesis. Supplementary devices feature CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures designed for mitral chordal replacement, as well as ascyrus medical dissection stents. Beyond products, the company offers pyrolytic carbon coating services to other medical device manufacturers. Artivion Inc. serves a broad client base, including physicians, hospitals, other healthcare facilities, and specialists such as cardiac, vascular, thoracic, and general surgeons. Established in 1984 and headquartered in Kennesaw, Georgia, the company adopted the name Artivion Inc. in January 2022, having previously operated as CryoLife, Inc.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Strong
72/100
Analyst data unavailable.

Latest News & Updates

News unavailable.